Literature DB >> 31215026

Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition.

Huanji Zhang1, Kun Zhang2, Jianwen Liang1, Wen Yan1, Fensheng Wu1, Wenmin Xu1, Zhiwen Wu1, Yixi Chen1, Rongquan Pan1, Guifu Wu1.   

Abstract

OBJECTIVES: To investigate the potential role and mechanism of TUPS, a soluble epoxide hydrolase inhibitor, in cardiac hypertrophy.
METHODS: Rat and H9C2 cell models of cardiac hypertrophy were induced by isoproterenol and angiotensin II, respectively, followed by TUPS treatment. The expression of hypertrophic markers, ANP and BNP, was determined by quantitative real-time PCR. The abundance of Beclin-1, LC3, p-AMPK and phosphorylated-mammalian target of rapamycin (p-mTOR) proteins was analysed by Western blot and immunohistocytology. Cell morphology and viability were evaluated by F-actin staining and MTS. H9C2 cells were transfected with GFP-LC3 to evaluate autophagy flux. KEY
FINDINGS: TUPS significantly inhibited rat heart size, heart weight-to-body weight ratio, heart wall thickness, hypertrophic H9C2 cell swelling and viability suppression as well as the expression of ANP and BNP genes in hypertrophic models. In addition, autophagic markers Beclin-1 and LC3 were elevated in both cellular and animal models, which were suppressed by TUPS, with corresponding changes of autophagy flux. The abundance of p-AMPK was increased, while p-mTOR was decreased in hypertrophic cells, which were abolished by TUPS. Rapamycin decreased p-mTOR level, increased Beclin-1 and LC3 expression and induced cell size enlargement and cell viability inhibition in hypertrophic H9C2 cells treated with TUPS.
CONCLUSIONS: TUPS inhibits cardiac hypertrophy by regulating mTOR/autophagy axis.
© 2019 Royal Pharmaceutical Society.

Entities:  

Keywords:  TUPS; autophagy; cardiac hypertrophy; mammalian target of rapamycin; soluble epoxide hydrolase inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31215026     DOI: 10.1111/jphp.13113

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.

Authors:  John D Imig; Wojciech K Jankiewicz; Abdul H Khan
Journal:  Hypertension       Date:  2020-06-01       Impact factor: 10.190

Review 2.  Epoxylipids and soluble epoxide hydrolase in heart diseases.

Authors:  John D Imig; Ludek Cervenka; Jan Neckar
Journal:  Biochem Pharmacol       Date:  2021-12-02       Impact factor: 5.858

Review 3.  Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.

Authors:  Cheng-Peng Sun; Xin-Yue Zhang; Christophe Morisseau; Sung Hee Hwang; Zhan-Jun Zhang; Bruce D Hammock; Xiao-Chi Ma
Journal:  J Med Chem       Date:  2020-12-28       Impact factor: 7.446

4.  Ginkgolide B Protects Cardiomyocytes from Angiotensin II-Induced Hypertrophy via Regulation of Autophagy through SIRT1-FoxO1.

Authors:  Qingyuan Jiang; Ming Lu; Jinyu Li; Zhongsheng Zhu
Journal:  Cardiovasc Ther       Date:  2021-06-23       Impact factor: 3.023

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.